Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dyslipidemia
Report: Dyslipidemia drug-treated population to grow 4% annually
September 27th, 2004
Decision Resources, Inc., forecasts that the overall dyslipidemia drug-treated population will increase by 4% annually. Primary factors driving the rise in drug treatment in this population include increasing awareness of its coronary heart disease risk coupled with the availability of low-cost, generic statin substitutes to treat these patients. The new Pharmacor study entitled "Dyslipidemia" also finds that Pfizer and Merck plan to fight back against generic erosion of atorvastatin and simvastatin, two leading statins. "The launch of Pfizer's atorvastatin/torcetrapib and atorvastatin/amlodipine, and of Merck/Schering-Plough's...
Source: Obesity & Diabetes Week (2004-09-27)
|
